Joint Venture8 Jul 2025, 11:01 pm
Lupin Ltd Enters into License and Supply Agreement with Zentiva, k.s. for Commercialization of Biosimilar Certolizumab Pegol
AI Summary
Lupin Ltd has entered into a License and Supply Agreement with Zentiva, k.s., for commercialization of Lupin’s biosimilar Certolizumab Pegol. Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories, whereas, Zentiva will oversee commercialization activities in Europe and CIS markets. The profits from the defined markets will be shared between the two companies. This collaboration aims to expand Lupin’s market reach and provide high-quality and cost-effective biosimilar to patients worldwide.
Key Highlights
- Lupin Ltd has entered into a License and Supply Agreement with Zentiva, k.s., for commercialization of Lupin’s biosimilar Certolizumab Pegol.
- Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories.
- Zentiva will oversee commercialization activities in Europe and CIS markets.
- The profits from the defined markets will be shared between the two companies.
- This collaboration aims to expand Lupin’s market reach and provide high-quality and cost-effective biosimilar to patients worldwide.